Novel compound improves symptoms of fatty liver disease in mice
The novel peripheral serotonin antagonist, based on Parkinson’s drug pimavanserin,…
The novel peripheral serotonin antagonist, based on Parkinson’s drug pimavanserin, increased glucose tolerance and lean body mass in a murine model of non-alcoholic fatty liver disease (NAFLD).